News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates.
Breaking Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas' VEPPANU becomes the first FDA-approved PROTAC drug for ESR1-mutated, ER+/HER2- advanced breast cancer, marking a breakthrough in protein degradation therapy.
Latest News
ISPOR 2026: Top Cardiology Innovations & Research Highlights
ISPOR 2026 cardiology sessions emphasized the critical role of health economics, real-world evidence, and digital health technologies in shaping cardiovascular drug development and clinical adoption strategies.
US-Japan Healthcare Conf: Key Takeaways for 2026
The 2026 U.S.-Japan Healthcare Conference highlighted expanding bilateral partnerships in regulatory harmonization, digital health innovation, and precision medicine—with particular emphasis on addressing shared demographic challenges and accelerating approval pathways for breakthrough therapies.
COG 2024: Key Highlights and Emerging Trends
NovaPharmaNews cannot publish pharmaceutical coverage of the 2nd Annual COG without verification of the event's actual focus, official agenda, and confirmed clinical data from authoritative sources.
BioNJ BioPartnering Conference: Key Biotech Innovations
The BioNJ BioPartnering Conference brought together biotech executives, pharmaceutical leaders, and venture capitalists to explore strategic partnerships and emerging innovations shaping the life sciences industry.
ASGCT: Key Manufacturing Innovations Day 1
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Day 1 focused on critical manufacturing innovations and scalability solutions for cell and gene therapies. Industry leaders discussed process optimization, quality control frameworks, and supply chain strategies essential to advancing CGT commercialization.
ASGCT 2024: Gene Therapy Advancements Day 1 Roundup
ASGCT 2024 convened leading researchers and clinicians to present advances in gene and cell therapy. The conference highlighted emerging therapeutic approaches and underscored growing industry investment in cell and gene therapy platforms.
Novo Nordisk Reports Record Q1 Revenue Driven by Wegovy and Ozempic Demand
Novo Nordisk has reported record Q1 revenue driven by strong demand for Wegovy and Ozempic. This article analyzes the implications for investors and the competitive landscape.
US-Japan Healthcare Conference: Day 1 Key Takeaways
The 2026 U.S.-Japan Healthcare Conference represents an important bilateral healthcare forum, but detailed Day 1 proceedings have not yet been released through official channels. NovaPharmaNews will provide verified coverage once official conference materials become available.
ISPOR 2026: Cardiology Advances in Cost-Effectiveness Research
ISPOR 2026 highlighted emerging cost-effectiveness frameworks for cardiovascular interventions and emphasized the critical role of real-world evidence in supporting value-based cardiology care and reimbursement decisions.
ASGCT 2024: Day 1 Key Takeaways in Gene Therapy Advancements
ASGCT 2024 Day 1 coverage: This article addresses data gaps in available materials while highlighting what readers should expect from gene and cell therapy presentations, regulatory updates, and manufacturing innovations discussed at the conference.
OCT East Coast: Key Takeaways from Day 1
NovaPharmaNews coverage of OCT East Coast Day 1 was limited by unavailable source materials. Readers are directed to official conference channels for comprehensive session details, speaker information, and clinical data presented.
BioMed Israel 2026: Key US Biotech Trends - Day 1 Roundup
BioMed Israel 2026 convened biotech stakeholders on Day 1, though comprehensive coverage of specific company presentations and announcements remains pending official conference materials and press releases.
BioNJ BioPartnering Conference: Biotech Innovation on Display
The BioNJ BioPartnering Conference convened biotech innovators, pharmaceutical executives, and investors to showcase emerging therapeutic platforms and forge strategic collaborations. The event highlighted trends in cell and gene therapy partnerships, rare disease focus, and early-stage venture investment.
BioMed Israel 2026: Key Takeaways for US Biotech Investors
BioMed Israel 2026 convened US and Israeli biotech stakeholders to explore partnership opportunities, showcasing innovations in diagnostics, drug delivery, and digital health while reinforcing the strategic importance of Israeli biotech within the US pharmaceutical investment landscape.
ASGCT 2026: Gene Therapy Manufacturing Innovations Emerge
ASGCT 2026 highlighted critical manufacturing innovations and challenges in gene therapy production, with industry leaders discussing vector scalability, automation adoption, and regulatory harmonization needs.
US-Japan Healthcare Conf. Day 1: Key Takeaways
The 2026 U.S.-Japan Healthcare Conference Day 1 focused on regulatory harmonization, digital health innovation, and policy alignment to strengthen bilateral pharmaceutical and healthcare collaboration. Key discussions addressed market access barriers, aging population health challenges, and emerging opportunities in personalized medicine.
BioNJ BioPartnering Conference: Day 1 Highlights
The BioNJ BioPartnering Conference convened New Jersey's biotech community on Day 1 to explore partnership opportunities, emerging technologies, and strategic collaborations. Sessions focused on partnership models, early-stage funding, regulatory pathways, and trends including AI-driven drug discovery and capital efficiency.
BioMed Israel: Day 1 Highlights in Biotech Innovation
BioMed Israel 2026 is anticipated to continue its role as a premier platform for biomedical innovation and international partnerships, though official details remain pending. This article provides historical context and anticipated focus areas based on previous editions.
US-Japan Healthcare Conf. Day 1: Key Policy & Tech Innovations
The 2026 U.S.-Japan Healthcare Conference Day 1 represents an important forum for bilateral collaboration on healthcare policy and innovation. However, comprehensive coverage requires verified official sources and speaker information.
ISPOR 2026: Cardiology Advances - Day 1 Roundup
NovaPharmaNews is monitoring ISPOR 2026 for cardiology and health economics content, but cannot publish Day 1 coverage without verified data, official abstracts, and named sources. We remain committed to accurate, fact-based reporting.